Journal ArticleDOI
Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer
Arlene A. Forastiere,Helmuth Goepfert,Moshe H. Maor,Thomas F. Pajak,Randal S. Weber,William H. Morrison,Bonnie S. Glisson,Andy Trotti,John A. Ridge,C. Chao,Glen Peters,Ding Jen Lee,Andrea Leaf,John F. Ensley,Jay S. Cooper +14 more
TLDR
In patients with laryngeal cancer, radiotherapy with concurrent administration of cisplatin is superior to induction chemotherapy followed by radiotherapy or radiotherapy alone for larynGEal preservation and locoregional control.Abstract:
Background Induction chemotherapy with cisplatin plus fluorouracil followed by radiotherapy is the standard alternative to total laryngectomy for patients with locally advanced laryngeal cancer. The value of adding chemotherapy to radiotherapy and the optimal timing of chemotherapy are unknown. Methods We randomly assigned patients with locally advanced cancer of the larynx to one of three treatments: induction cisplatin plus fluorouracil followed by radiotherapy, radiotherapy with concurrent administration of cisplatin, or radiotherapy alone. The primary end point was preservation of the larynx. Results A total of 547 patients were randomly assigned to one of the three study groups. The median follow-up period was 3.8 years. At two years, the proportion of patients who had an intact larynx after radiotherapy with concurrent cisplatin (88 percent) differed significantly from the proportions in the groups given induction chemotherapy followed by radiotherapy (75 percent, P=0.005) or radiotherapy alone (70 ...read more
Citations
More filters
Journal ArticleDOI
Transoral laser microsurgery for recurrent laryngeal and pharyngeal cancer.
David G. Grant,John R. Salassa,Michael L. Hinni,Bruce W. Pearson,Richard E. Hayden,William C. Perry +5 more
TL;DR: Transoral laser microsurgery offers select patients an attractive alternative salvage surgical therapy to the recurrent and second primary tumor site to reduce the likelihood of future treatment-related deaths.
Journal ArticleDOI
Randomized phase III trial comparing induction chemotherapy followed by radiotherapy to concomitant chemoradiotherapy for laryngeal preservation in T3M0 pyriform sinus carcinoma
Jean-Michel Prades,Benjamin Lallemant,Renaud Garrel,Emile Reyt,Christian Righini,Thierry M. Schmitt,Nagib Remini,Lea Saban-Roche,Andrei P. Timoshenko,Beatrice Trombert,Bernard Guerrier +10 more
TL;DR: Conventional radiotherapy with concurrent cisplatin is significantly superior to induction cisPlatin fluorouracil chemotherapy followed by radiotherapy in terms of laryngeal preservation in patients with T3 hypopharyngeAL carcinoma.
Journal ArticleDOI
Cisplatin Eligibility Issues and Alternative Regimens in Locoregionally Advanced Head and Neck Cancer: Recommendations for Clinical Practice.
Petr Szturz,Valerie Cristina,Ruth Gabriela Herrera Gomez,Jean Bourhis,Christian Simon,Jan B. Vermorken +5 more
TL;DR: To facilitate triaging of medical information, available publications on chemoradiotherapy of locally advanced squamous cell carcinoma of the head and neck were reviewed and practice-oriented recommendations for systemic treatment concurrent to definitive and post-operative radiotherapy were prepared.
Journal ArticleDOI
A randomized phase III trial of cisplatin and tumor volume directed irradiation followed by carboplatin and paclitaxel vs. carboplatin and paclitaxel for optimally debulked, advanced endometrial carcinoma.
Daniela Matei,Virginia L. Filiaci,Marcus E. Randall,Margaret M. Steinhoff,Paul DiSilvestro,Katherine M. Moxley,Byoung Joon Kim,Matthew A. Powell,David M. O'Malley,Nicola M. Spirtos,Krishnansu S. Tewari,Wm Edward Richards,John Nakayama,David G. Mutch,David Miller +14 more
TL;DR: This open label, randomized phase III trial was to determine if treatment with cisplatin and volume-directed radiation followed by carboplatin and paclitaxel for 4 cycles reduces the rate of recurrence or death or increases recurrence-free survival, RFS.
Journal ArticleDOI
Inhibition of TGF-β Enhances the In Vivo Antitumor Efficacy of EGF Receptor–Targeted Therapy
Atul Bedi,Xiaofei Chang,Kimberly A. Noonan,Vui Pham,Rishi Bedi,Elana J. Fertig,Michael Considine,Joseph A. Califano,Ivan Borrello,Christine H. Chung,David Sidransky,Rajani Ravi +11 more
TL;DR: Elevated levels of TGF-β in the tumor microenvironment enable tumor cells to evade ADCC and resist the antitumor activity of cetuximab in vivo, and provide a rationale for combinatorial targeting of T GF-β to improve anti-EGFR–specific antibody therapy of EGFR-expressing cancers.
References
More filters
Book ChapterDOI
Nonparametric Estimation from Incomplete Observations
Edward L. Kaplan,Paul Meier +1 more
TL;DR: In this article, the product-limit (PL) estimator was proposed to estimate the proportion of items in the population whose lifetimes would exceed t (in the absence of such losses), without making any assumption about the form of the function P(t).
Journal Article
Evaluation of survival data and two new rank order statistics arising in its consideration.
Journal ArticleDOI
A Multiple Comparison Procedure for Comparing Several Treatments with a Control
TL;DR: In this article, a multiple comparison procedure for comparing several treatments with a control is presented, which is based on the Multiple Comparison Procedure for Comparing Several Treatments with a Control (MCPC).
Journal ArticleDOI
A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
TL;DR: In this paper, a class of tests developed for comparing the cumulative incidence of a particular type of failure among different groups is presented. The tests are based on comparing weighted averages of the hazards of the subdistribution for the failure type of interest.
Journal ArticleDOI
Cancer statistics, 2003.
TL;DR: The American Cancer Society estimates the number of new cancer cases and deaths expected in the United States in the current year, and compiles the most recent data on cancer incidence, mortality, and survival by using incidence data from the National Cancer Institute (NCI) and mortality data from National Center for Health Statistics (NCHS).